Can Sanofi compete in lung cancer? With I-O med cemiplumab, it’s aiming for third

Can Sanofi compete in lung cancer? With I-O med cemiplumab, it’s aiming for third

Source: 
Fierce Pharma
snippet: 

Same or different—that’s a big question rattling around the immuno-oncology field, where PD-1 and PD-L1 checkpoint inhibitors have put up differing results in clinical trials.

The assessment from Sanofi? The PD-1 drugs themselves are essentially equal. It’s the trial designs that make them look different, Joanne Lager, head of oncology development, said in an interview Wednesday.